Manufacturing Injectables in the Multiplex describes a strategy to achieve flexibility and scale in biopharmaceutical manufacturing.
“The companies that are adopting the Multiplex strategy are beating traditional supply chains in terms of cost of goods, time to market and quality,” says Chris Procyshyn, CEO of Vanrx. “The pillars of the Multiplex are becoming a movement among the market leaders, so this is a must-read for executives looking to create a sustainable competitive advantage.”
On November 6 at AAPS, Markus Stübchen, Roche’s Global Technical Lead for Large Molecule Drug Product & Clean Utilities, delivered the presentation Novel Approaches for Robotics Use in Sterile Manufacturing. The presentation described how Roche / Genentech will use Vanrx's SA25 as part of a "network" strategy.Read More